Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer

NCT01774071 | Completed Phase 1 Results

• 1 other identifier: 12-178
• Study Type: interventional
• Target: 19
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to see if a new diagnostic research agent named 89Zr-DFO-MSTP2109A can show prostate cancer tumors on a PET scan; as well as see how long 89Zr-DFO-MSTP2109A lasts in the blood when given in small amounts. DFO-MSTP2109A is an antibody that works against STEAP1 - found on the surface of prostate cancer cells. Attached to the DFO-MSTP2109A is a radioactive material called 89ZR, which allows it to be imaged by a PET scanner. The results of this study may help researchers know whether 89Zr-DFO-MSTP2109A can be used as a diagnostic agent for finding prostate cancer that have STEAP1 on its surface with a PET scanner. The reason why identifying STEAP1 on prostate cancer cells is that new therapies are being developed to target STEAP1 prostate cancer cells.

Conditions

Prostate Cancer

Keywords

89Zr-DFO-MSTP2109A; tracer; pet scan; 12-178

Outcome Measures

Primary Outcomes (4)

• Percentage of Participants With Histologically Positive Lesions That Are Positive on Imaging

  Antibody imaging will be considered feasible if 75% of the patients are antibody-imaging-positive. We will enroll 6 patients (cohort 1A) at the 10mg dose level for an initial decision on feasibility. If 4 or more of these patients have 20% or more of their active lesions detectable by 89Zr-DFO-MSTP2109A then we will consider the agent feasible for imaging, otherwise we will proceed to cohort 1B. If the true feasibility rate is 40%, this rule will affords more than 82% chance that cohort 1B will be opened for enrollment; this probability is less than 17% if the true feasibility is 75%.

  2 years

• Number of Participants Evaluated for AEs

  All participants will be evaluated for adverse events which will be graded for intensity on a scale of 0 to 5. Severity grades will be recorded and based on the CTCAE v4.0. Adverse events will be defined graded using CTCAE V4.0.

  2 years

• Rate of Clearance of Tracer 89Zr-DFO-MSTP2109A

  Serial blood draws will be used to estimate the pharmacokinetic profile of the 10mg 89Zr-DFO-MSTP2109A in this patient population. Blood samples will be obtained in green top tube: Just prior to injection of 89Zr-DFO-MSTP2109A (baseline)Approximately 5 ± 2, 15 ± 5, 30 ± 9, 60 ± 19, and 120 to 240 minutes after injection of the tracer. One sample at the time of each subsequent day of imaging (24 + 8h, \~48-96h and \~120-168h post injection).

  up to 168 hours

• Biodistribution/SUVmax

  A PET-CT scan extending from top of skull to mid thighs will be performed to determine the biodistribution/SUVmax in bone and soft tissue

  2 years

Secondary Outcomes (1)

• Percentage of Histologically Positive Lesions That Were True Positive on PET Imaging

  2 years

Study Arms (2)

89Zr DFOMSTP2109A tracer Group 1

EXPERIMENTAL

The first group of participants will include 6 participants whom will receive 10mg of 89Zr-DFO-MSTP2109A. A second group of 6 participants may receive twice the amount of antibody to determine if this results in better pictures of your tumors. Once we determine whether 10 mg or the larger 20 mg dose of 89Zr-DFOMSTP2109A is best and well tolerated we will use that amount for future participants in Group 2.

Drug: 89Zr- DFO-MSTP2109A

89Zr-DFO-MSTP2109A tracer Group 2

EXPERIMENTAL

Once we determine whether 10 mg or the larger 20 mg dose of 89Zr-DFOMSTP2109A is best and well tolerated we will use that amount for future participants in Group 2. Group 2 will include up to 15 participants whom may receive a dose of up to 20mg.

Drug: 89Zr DFO-MSTP2109A

Interventions

89Zr DFO-MSTP2109A DRUG

If you are enrolled onto Group 2: Once you are given the study drug, the following procedures will be done: You will have one PET scan done. The timing of the PET scan will be determined at the time of your enrollment (\~ 3-7 days after injection). No research blood work will be drawn in Group 2

89Zr-DFO-MSTP2109A tracer Group 2

Eligibility Criteria

• Age: 21 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• To be included in this study, patients should be eligible for enrollment into protocol 11-016 (therapy with the DSTP3086S ADC) or meet all of the following criteria:
• Patients meeting the criteria for enrollment on research protocol 11-016 to receive DSTP3086S ADC (therapeutic ADC based on MSTP2109A) will be the preferred patients for this study. Patients that are to receive DSTP3086S will not be injected with DSTP2086S until imaging with 89Zr-DFOMSTP2109A is finished, approximately 1 week.
• Adult male \> 21years of age
• Visible lesions by either CT, bone scan or MRI consistent with metastatic disease
• Metastatic progressive disease
• Imaging modalities:
• Bone scan: new osseous lesion and/or MRI or CT: An increase in measurable soft tissue disease or the appearance of new sites of disease.
• PSA changes over range of value 26%
• Patients with histologically confirmed prostate cancer at MSKCC
• STEAP1 antigen positive tissue known from prior IHC testing or if STEAP1 status is not known archival sample will be sent to Genentech for IHC. Samples need to be positive, when feasible metastatic lesions will be tested preferentially rather than the primary.
• Performance status of 60 or higher (Karnofsky scale) (Appendix A)
• Ability to understand and willingness to sign a written informed consent document
• PSA levels to be taken within 2 weeks of antibody administration.

You may not qualify if:

• Previous anaphylactic reaction to human, humanized or chimeric antibody
• Hematologic
• Platelets \<75K/mcL
• ANC \<1.0 K/mcL
• Hepatic laboratory values
• AST/ALT \>2.5 x ULN
• Renal laboratory values
• Bilirubin \>1.5 x ULN (institutional upper limits of normal)
• eGFR \< 30mL/min/1.73m2
• Patients with history of hypersensitivity reaction to any component of 89Zr-DFOMSTP2109A, including DFO

Sponsors & Collaborators

• Memorial Sloan Kettering Cancer Center: lead
• Genentech, Inc.: collaborator

Study Sites (1)

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

Location

Related Publications (1)

• Martiniova L, Zielinski RJ, Lin M, DePalatis L, Ravizzini GC. The Role of Radiolabeled Monoclonal Antibodies in Cancer Imaging and ADC Treatment. Cancer J. 2022 Nov-Dec 01;28(6):446-453. doi: 10.1097/PPO.0000000000000625.

  PMID: 36383907 DERIVED

Related Links

• Memorial Sloan Kettering Cancer Center

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Results Point of Contact

• Title: Dr. Steven Larson, MD
• Organization: Memorial Sloan Kettering Cancer Center

LarsonS@MSKCC.ORG

646-888-2212

Study Officials

• Steven Larson, MD

  Memorial Sloan Kettering Cancer Center

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 11, 2013
• First Posted: January 23, 2013
• Study Start: January 1, 2013
• Primary Completion: May 2, 2023
• Study Completion: May 2, 2023
• Last Updated: October 2, 2024
• Results First Posted: October 2, 2024

Record last verified: 2024-05

Locations

US (1)